This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Long-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder: An Open-Label Continuation Phase Study

Todd M. Sanger, Starr L. Grundy, P. Joseph Gibson, Madhav A. Namjoshi, Michael G. Greaney, and Mauricio F. Tohen

Published: April 1, 2001

Article Abstract

Background: Olanzapine has demonstrated efficacyin the treatment of acute mania in 2 double-blind,placebo-controlled trials. We describe the results of theopen-label extension from one of these trials.

Method: In a 3-week, double-blind study ofpatients with DSM-IV bipolar I disorder, olanzapine was superiorto placebo for the treatment of acute manic symptoms. Of the 139patients who entered the double-blind phase of the 3-week study,113 patients continued into the 49-week open-label extension.Efficacy measurements including the Young Mania Rating Scale(YMRS), the 21-item Hamilton Rating Scale for Depression(HAM-D-21), the Clinical Global Impressions scale-BipolarVersion, and the Positive and Negative Syndrome Scale and safetymeasurements including the Simpson-Angus scale, the BarnesAkathisia Scale, and the Abnormal Involuntary Movement Scale werecompleted throughout. The analysis considered all treatmentresults, starting with the first olanzapine dose. Adjunctivelithium and fluoxetine were allowed during the open-labelextension.

Results: The mean length of olanzapinetreatment was 6.6 months, with a mean modal dose of 13.9 mg/day.A significant mean improvement in the YMRS total score, baselineto endpoint (-18.01, p < .001), was observed. Duringtreatment, 88.3% of patients experienced a remission ofmanic symptoms (YMRS total score = 15). Significantimprovement in HAM-D-21 scores was observed (p < .001).Forty-one percent of patients were maintained on olanzapinemonotherapy. The most common treatment-emergent adverse eventsreported were somnolence (46.0%), depression (38.9%), and weightgain (36.3%).

Conclusion: During up to 1 year of olanzapinetherapy, either as monotherapy or in combination with lithiumand/or fluoxetine, patients with bipolar disorder demonstratedsignificant improvement in mania and depression symptoms with afavorable safety profile. Further double-blind, controlledstudies are needed to confirm these results.

Volume: 62

Quick Links: Bipolar Disorder

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...